This pharmaceutical company transformed net losses into astonishing net profits!

This pharmaceutical company transformed net losses into astonishing net profits!

by 5paisa Research Team Last Updated: May 11, 2023 - 09:54 am 119 Views

Fourth quarter and year ended March 31, 2023 results were reported by Lupin Ltd. 

Quarterly Performance

Comparing the fourth quarter of 2023 to the same quarter the year prior, the company reported a net profit of Rs 242.39 crore on a consolidated basis as opposed to a net loss of Rs 511.73 crore. In Q4FY23, the company's total revenue climbed by 14.59% to Rs 4,467.35 crore from Rs 3,898.71 crore in the similar quarter the year prior. 

The company declared a net profit of Rs 447.69 crore for the fiscal year that ended on March 31, 2023, as opposed to a net loss of Rs 1,509.36 crore the year before. When compared to the year ended March 31, 2022, the company's total revenue increased by 1.01% to Rs 16,715.02 crore from Rs 16,541.17 crore during the year under review. 

Share Price Movement: 

In the last trading session script closed at Rs 745.80 and today it opened at Rs 752. Currently, it is trading at Rs 742.10. Till now the scrip has touched a high and low of Rs 753 and Rs 734.25, respectively. So far 68,086 shares were traded on the counter at BSE. 

It has a 52-week high and low of Rs 788.90 and 583.05, respectively. It is BSE group 'A' stock with a face value of Rs 2 and a market cap of Rs 33,751.54 crore. 

Company Profile

Lupin manufactures pharmaceuticals as a part of its business. It developed into one of the world's fastest-growing generic pharmaceutical enterprises. Lupin is regarded as one of the biggest producers of anti-tuberculosis medications worldwide. The company holds a large market position in a number of therapeutic categories, including those for the cardiovascular system, diabetes, asthma, digestive tract, central nervous system, and non-steroidal anti-inflammatory drugs (NSAIDs). Additionally, the business has been proud to hold onto its global leadership positions in other therapy areas including anti-TB and cephalosporin over the years. 

How do you rate this article?


Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.


Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial. Also, The

Open Free Demat Account

Resend OTP
Please Enter OTP
Account belongs to

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number